Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF

Hansson, Oskar LU orcid ; Rutz, Sandra ; Zetterberg, Henrik LU ; Bauer, Ekaterina ; Hähl, Teresa ; Manuilova, Ekaterina ; Mert, Mehmet Can ; Wahl, Simone ; Blennow, Kaj LU and Stomrud, Erik LU orcid (2020) In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 12(1).
Abstract

Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. Results: Amyloid beta (Aβ)1-42 levels varied by tube type, using a low-bind FBT reduced variation. Aβ1-42 levels were higher with no mixing versus... (More)

Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. Results: Amyloid beta (Aβ)1-42 levels varied by tube type, using a low-bind FBT reduced variation. Aβ1-42 levels were higher with no mixing versus roller/inversion mixing. Aβ1-42 levels were lower with horizontal versus upright transportation; this was resolved by maximal tube filling and storage at 2°C to 8°C. Aβ1-40 levels were less strongly affected. Phospho-tau and total-tau levels were largely unaffected. Discussion: We propose an easy-to-use, standardized, routine-use pre-analytical protocol, using low-bind FBTs, for measuring AD CSF biomarkers in clinical practice.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, amyloid beta, biomarker, cerebrospinal fluid, diagnosis, pre-analytical, tau
in
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
volume
12
issue
1
article number
e12137
publisher
Elsevier
external identifiers
  • pmid:33354617
  • scopus:85100542916
ISSN
2352-8729
DOI
10.1002/dad2.12137
language
English
LU publication?
yes
id
317648db-aa5e-433d-8c0a-938df9a2344d
date added to LUP
2021-02-26 14:28:47
date last changed
2025-11-30 00:52:16
@article{317648db-aa5e-433d-8c0a-938df9a2344d,
  abstract     = {{<p>Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments, except tube types/sterilization experiments. Biomarkers were measured using Elecsys CSF assays. Results: Amyloid beta (Aβ)<sub>1-42</sub> levels varied by tube type, using a low-bind FBT reduced variation. Aβ<sub>1-42</sub> levels were higher with no mixing versus roller/inversion mixing. Aβ<sub>1-42</sub> levels were lower with horizontal versus upright transportation; this was resolved by maximal tube filling and storage at 2°C to 8°C. Aβ<sub>1-40</sub> levels were less strongly affected. Phospho-tau and total-tau levels were largely unaffected. Discussion: We propose an easy-to-use, standardized, routine-use pre-analytical protocol, using low-bind FBTs, for measuring AD CSF biomarkers in clinical practice.</p>}},
  author       = {{Hansson, Oskar and Rutz, Sandra and Zetterberg, Henrik and Bauer, Ekaterina and Hähl, Teresa and Manuilova, Ekaterina and Mert, Mehmet Can and Wahl, Simone and Blennow, Kaj and Stomrud, Erik}},
  issn         = {{2352-8729}},
  keywords     = {{Alzheimer's disease; amyloid beta; biomarker; cerebrospinal fluid; diagnosis; pre-analytical; tau}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Elsevier}},
  series       = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}},
  title        = {{Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF}},
  url          = {{http://dx.doi.org/10.1002/dad2.12137}},
  doi          = {{10.1002/dad2.12137}},
  volume       = {{12}},
  year         = {{2020}},
}